These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 21616658

  • 1. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism.
    Nie Q, Yang XN, An SJ, Zhang XC, Yang JJ, Zhong WZ, Liao RQ, Chen ZH, Su J, Xie Z, Wu YL.
    Eur J Cancer; 2011 Sep; 47(13):1962-70. PubMed ID: 21616658
    [Abstract] [Full Text] [Related]

  • 2. EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib.
    Winther Larsen A, Nissen PH, Meldgaard P, Weber B, Sorensen BS.
    Lung Cancer; 2014 Sep; 85(3):435-41. PubMed ID: 25017413
    [Abstract] [Full Text] [Related]

  • 3. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA, Johnson BE.
    Clin Cancer Res; 2006 Jul 15; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [Abstract] [Full Text] [Related]

  • 4. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
    Tiseo M, Rossi G, Capelletti M, Sartori G, Spiritelli E, Marchioni A, Bozzetti C, De Palma G, Lagrasta C, Campanini N, Camisa R, Boni L, Franciosi V, Rindi G, Ardizzoni A.
    Lung Cancer; 2010 Mar 15; 67(3):355-60. PubMed ID: 19473722
    [Abstract] [Full Text] [Related]

  • 5. Shorter EGFR Dinucleotide Repeat Length Predicts Better Response of Patients with Advanced Non-small Cell Lung Cancer to EGFR Tyrosine Kinase Inhibitor.
    Chen B, Luo J, Gu W, Shen L, Wang H, Zhou S.
    Cell Biochem Biophys; 2015 Dec 15; 73(3):799-804. PubMed ID: 27259328
    [Abstract] [Full Text] [Related]

  • 6. Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib.
    Ma F, Sun T, Shi Y, Yu D, Tan W, Yang M, Wu C, Chu D, Sun Y, Xu B, Lin D.
    Lung Cancer; 2009 Oct 15; 66(1):114-9. PubMed ID: 19201048
    [Abstract] [Full Text] [Related]

  • 7. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
    Roengvoraphoj M, Tsongalis GJ, Dragnev KH, Rigas JR.
    Cancer Treat Rev; 2013 Dec 15; 39(8):839-50. PubMed ID: 23768755
    [Abstract] [Full Text] [Related]

  • 8. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
    Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT, Chen YM, Perng RP, Tsai SF, Tsai CM.
    Clin Cancer Res; 2005 May 15; 11(10):3750-7. PubMed ID: 15897572
    [Abstract] [Full Text] [Related]

  • 9. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
    Bonomi PD, Buckingham L, Coon J.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
    [Abstract] [Full Text] [Related]

  • 10. Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer.
    Tiseo M, Capelletti M, De Palma G, Franciosi V, Cavazzoni A, Mozzoni P, Alfieri RR, Goldoni M, Galetti M, Bortesi B, Bozzetti C, Loprevite M, Boni L, Camisa R, Rindi G, Petronini PG, Ardizzoni A.
    J Thorac Oncol; 2008 Oct 01; 3(10):1104-11. PubMed ID: 18827605
    [Abstract] [Full Text] [Related]

  • 11. Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib.
    Winther-Larsen A, Nissen PH, Jakobsen KR, Demuth C, Sorensen BS, Meldgaard P.
    Lung Cancer; 2015 Nov 01; 90(2):314-20. PubMed ID: 26386832
    [Abstract] [Full Text] [Related]

  • 12. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer.
    Kawahara A, Taira T, Azuma K, Tominaga M, Hattori S, Kawahara M, Abe H, Yamaguchi T, Akiba J, Takamori S, Hayashi A, Kage M.
    Lung Cancer; 2012 Oct 01; 78(1):39-44. PubMed ID: 22858448
    [Abstract] [Full Text] [Related]

  • 13. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
    Gately K, O'Flaherty J, Cappuzzo F, Pirker R, Kerr K, O'Byrne K.
    J Clin Pathol; 2012 Jan 01; 65(1):1-7. PubMed ID: 22039281
    [Abstract] [Full Text] [Related]

  • 14. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
    Yi HG, Kim HJ, Kim YJ, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Kim CS, Heo DS, Bang YJ.
    Lung Cancer; 2009 Jul 01; 65(1):80-4. PubMed ID: 19059670
    [Abstract] [Full Text] [Related]

  • 15. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer.
    Wang S, An T, Wang J, Zhao J, Wang Z, Zhuo M, Bai H, Yang L, Zhang Y, Wang X, Duan J, Wang Y, Guo Q, Wu M.
    Clin Cancer Res; 2010 Feb 15; 16(4):1324-30. PubMed ID: 20145159
    [Abstract] [Full Text] [Related]

  • 16. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors.
    Cohen V, Agulnik JS, Ang C, Kasymjanova G, Batist G, Small D, Brandao G, Chong G, Miller WH.
    Cancer; 2010 Sep 15; 116(18):4309-17. PubMed ID: 20549828
    [Abstract] [Full Text] [Related]

  • 17. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.
    Su KY, Chen HY, Li KC, Kuo ML, Yang JC, Chan WK, Ho BC, Chang GC, Shih JY, Yu SL, Yang PC.
    J Clin Oncol; 2012 Feb 01; 30(4):433-40. PubMed ID: 22215752
    [Abstract] [Full Text] [Related]

  • 18. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
    Chang MH, Ahn HK, Lee J, Jung CK, Choi YL, Park YH, Ahn JS, Park K, Ahn MJ.
    Cancer; 2011 Jan 01; 117(1):143-51. PubMed ID: 20803614
    [Abstract] [Full Text] [Related]

  • 19. Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR.
    Chung KP, Wu SG, Wu JY, Yang JC, Yu CJ, Wei PF, Shih JY, Yang PC.
    Clin Cancer Res; 2012 Jun 15; 18(12):3470-7. PubMed ID: 22510346
    [Abstract] [Full Text] [Related]

  • 20. Reaction of plasma adiponectin level in non-small cell lung cancer patients treated with EGFR-TKIs.
    Umekawa K, Kimura T, Kudoh S, Suzumura T, Nagata M, Mitsuoka S, Matsuura K, Oka T, Yoshimura N, Kira Y, Hirata K.
    Osaka City Med J; 2013 Jun 15; 59(1):53-60. PubMed ID: 23909081
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.